A specialty pharmaceutical company with products marked in the U.S. and Europe. Acquired by Elan Corporation
Employees: 10001+
Founded date: 1969
Investors 2
| Date | Name | Website |
| - | Horizon Ve... | horizonvc.... |
| - | Signet Hea... | signetheal... |
Mentions in press and media 9
| Date | Title | Description |
| 24.01.2012 | Former BNP Sunstone chairman joins cancer vaccine firm’s board | Last month, Berwyn, Pennsylvania-based Formula announced it was raising $13 million in a series B financing round to move a vaccine to be used during first remission for acute myeloid leukemia and other aggressive cancers through phase 2 cl... |
| 20.01.2012 | Multiple sclerosis: BIIB’s Tysabri gets FDA O.K. on test, label change | The FDA also granted Weston, Massachusetts-based Biogen Iden a label change for Tysabri that updates the risk factors of developing PML for MS and Crohn’s disease patients. RBC Capital Markets analyst Michael Yee told Bloomberg News that th... |
| 27.06.2011 | Alzheimer’s disease drug company Curaxis shuffles management, board | Curaxis’s focus is on developing new treatments for Alzheimer’s disease. Alzheimer’s Disease International estimates that there are 35.6 million people worldwide with dementia. The group projects that that number will increase to 115.4 mill... |
| 01.02.2010 | Infosys Technologies and Elan Pharmaceuticals Apply Co-creation Model to Transform Discovery Research | Elan Pharmaceuticals Leverages Infosys Scientific Innovation Solution for New Research Informatics System London, UK – February 1, 2010: Infosys Technologies Limited (NASDAQ: INFY) today announced that it will design and implement the Resea... |
| 22.08.2007 | Life sciences briefing: Wednesday, Aug. 22, 2007 | Featured companies: Alpex Pharma, Applied Computational Technologies, Separation Design Group, ThermalTherapeutics Systems Switzerland’s Alpex Pharma raises $9M for plop, plop, fizz, fizz drugs– Alpex Pharma, a Mezzovico, Switzerland drug-f... |
| 30.05.2007 | Roundup: Genetic links to breast cancer, Avandia under attack, death and the drug official, and more | More genetic links for breast cancer — Whole-genome association studies that tease out links between minute genetic variations and the likelihood of disease are definitely building momentum. Over the last several days, researchers reported ... |
| - | Alzheimer’s disease drug company Curaxis shuffles management, board | Alzheimer’s disease drug development company Curaxis Pharmaceutical (OTC:CURX) is overhauling its operations with a swap out of both the management team and the board of directors. Taking over as chairman of Curaxis’s board and interim CEO ... |
| - | Former BNP Sunstone chairman joins cancer vaccine firm’s board | The former chairman of BNP Sunstone and a pharmaceutical veteran has joined the board of a firm developing a cancer vaccine. Martyn Greenacre has served as a CEO of Delsys Pharmaceutical Corp., a formulation and drug-delivery system company... |
| - | Multiple sclerosis: BIIB’s Tysabri gets FDA O.K. on test, label change | Multiple sclerosis patients using Biogen Idec (NASDAQ:BIIB) drug Tysabri now have access to the first test that can help determine their risk for developing a rare but potentially fatal brain infection that affects some patients using the d... |